All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Issues CRL for Odronextamab in Relapsed/Refractory Follicular Lymphoma

August 1st 2025

The FDA has issued a complete response letter for odronextamab in relapsed or refractory follicular lymphoma.

China’s NMPA Accepts sNDA for Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous NSCLC

July 31st 2025

Ivonescimab plus chemotherapy is under review in China for the frontline treatment of patients with advanced squamous non–small cell lung cancer.

Close Collaboration Between Oncology and Neurology Vital in Managing Patients With NAIDs Receiving ICIs for Cancer

July 31st 2025

Shailee S. Shah, MD, discusses the frequency and severity of neurologic autoimmune disorder exacerbation in patients with cancer receiving ICIs.

CLD-201 Viral Therapy Receives FDA Fast Track Designation for Soft Tissue Sarcoma

July 31st 2025

The first-in-class, allogeneic stem cell–loaded oncolytic virus CLD-201 was granted FDA fast track designation for the treatment of soft tissue sarcoma.

Forbes Names Roswell Park One of America’s Best Employers for Women 2025

July 31st 2025

A New York cancer center appears on list for second consecutive year, based on anonymous employee surveys

Asciminib Nets Canadian Approval in Newly Diagnosed and Previously Treated Ph+ CML

July 31st 2025

Health Canada has expanded the approval of asciminib to include newly diagnosed and pretreated Ph-positive CML.

Frontline IMM2510 Plus Chemo Drives Responses in Advanced NSCLC

July 31st 2025

IMM2510 plus chemotherapy generated responses in the first-line treatment of advanced non–small cell lung cancer.

Revisit Every OncLive On Air Episode From July 2025

July 31st 2025

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

Hemoglobin Improvement With Momelotinib Confers OS Benefit in Myelofibrosis With Anemia

July 31st 2025

Francesca Palandri, MD, PhD, discusses findings from a post hoc analysis of momelotinib-induced hemoglobin level improvements in myelofibrosis with anemia.

Geneva HRD Test Predicts Survival Benefit From Olaparib Plus Bevacizumab in Advanced Ovarian Cancer

July 31st 2025

The Geneva HRD test was predicitive for OS and PFS benefits with olaparib plus bevacizumab in advanced ovarian cancer.

Biomarkers May Inform Potential Role for Ipilimumab/Nivolumab in Untreated Metastatic Urothelial Cancer After Missing OS End Point

July 30th 2025

Guru P. Sonpavde, MD, discusses the role of ipilimumab/nivolumab after negative trial results in managing advanced urothelial cancer.

FDA Grants Fast Track Designation to Ateganosine for NSCLC

July 30th 2025

The FDA has granted fast track designation to ateganosine for non–small cell lung cancer.

FDA Approval of Dato‑DXd Expands Options for HR+, HER2‑Negative Metastatic Breast Cancer

July 30th 2025

Aditya Bardia, MD, MPH, discusses how Dato‑DXd serves as a new treatment option with a distinct safety profile in HR-positive, HER2‑negative breast cancer.

MD Anderson and TOPPAN Holdings Announce Strategic Alliance to Co-Develop Organoid Technology for Evaluating Cancer Treatments

July 30th 2025

Collaboration will aim to obtain CAP/CLIA certification of organoid-based assay, followed by clinical studies in multiple indications

First-Line Onvansertib Plus Bevacizumab and Chemo Yields Responses in RAS-Mutated mCRC

July 30th 2025

Onvansertib plus SOC generated responses with a tolerable safety profile in patients with previously untreated RAS-mutated metastatic colorectal cancer.

Namodenoson Surpasses Halfway Enrollment Benchmark in Advanced Pancreatic Cancer Trial

July 30th 2025

Can-Fite has reached the over 50% enrollment milestone for an ongoing phase 2a trial evaluating namodenoson in pancreatic cancer.

Trispecific Antibodies, Novel CAR T-Cell Therapies Signal Progress in R/R Myeloma

July 30th 2025

Joshua Richter, MD, outlines how trispecific antibodies and novel CAR T-cell therapies are shaping the 2025 myeloma landscape and improving patient access.

Additive IL-6 Inhibition Improves ICI-Related Response Rates and Safety in Advanced Melanoma

July 30th 2025

Janice Mehnert, MD, discusses the rationale for adding IL-6 inhibition to an ICI backbone and data with sarilumab plus ICIs in advanced melanoma.

IMproveMF Trial Shows Early Potential of Imetelstat Plus Ruxolitinib in Myelofibrosis

July 30th 2025

John Mascarenhas, MD, discusses early findings from the IMproveMF trial combining imetelstat with ruxolitinib in intermediate- to high-risk myelofibrosis.

Dual SVR/TI Response With Momelotinib Confers OS Benefit in Myelofibrosis With Anemia and Low Platelet Counts

July 29th 2025

Francesca Palandri, MD, PhD, discusses the results from a subgroup analysis of momelotinib vs ruxolitinib in myelofibrosis with anemia and low platelet counts.